相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Review: genetic models of acute myeloid leukaemia
E. McCormack et al.
ONCOGENE (2008)
Chemotherapy-resistant human AML stem cells home to and engraft within the bone-marrow endosteal region
Fumihiko Ishikawa et al.
NATURE BIOTECHNOLOGY (2007)
CD33 expression and P-glycoprotein-mediated drug efflux inversely correlate and predict clinical outcome in patients with acute myeloid leukemia treated with gemtuzumab ozogamicin monotherapy
Roland B. Walter et al.
BLOOD (2007)
The role of Gemtuzumab Ozogamicin in the treatment of acute myeloid leukemia patients
L. Pagano et al.
ONCOGENE (2007)
Subclassification of patients with acute myelogenous leukemia based on chemokine responsiveness and constitutive chemokine release by their leukemic cells
Oystein Bruserud et al.
HAEMATOLOGICA (2007)
Engineered anti-CD70 antibody with multiple effector functions exhibits in vitro and in vivo antitumor activities
Julie A. McEarchern et al.
BLOOD (2007)
High efficacy and safety profile of fractionated doses of Mylotarg as induction therapy in patients with relapsed acute myeloblastic leukemia: a prospective study of the alfa group
A-L Taksin et al.
LEUKEMIA (2007)
Cytogenetics and age are major determinants of outcome in intensively treated acute myeloid leukemia patients older than 60 years:: Results from AMLSG trial AML HD98-B
Stefan Froehling et al.
BLOOD (2006)
JTE-607, a multiple cytokine production inhibitor, ameliorates disease in a SCID mouse xenograft acute myeloid leukemia model
Naofumi Uesato et al.
EXPERIMENTAL HEMATOLOGY (2006)
Therapeutic potential of cytokine and chemokine antagonists in cancer therapy
L Yan et al.
EUROPEAN JOURNAL OF CANCER (2006)
AML engraftment in the NOD/SCID assay reflects the outcome of AML: implications for our understanding of the heterogeneity of AML
DJ Pearce et al.
BLOOD (2006)
Hematopoietic stem cells express multiple myeloid markers: implications for the origin and targeted therapy of acute myeloid leukemia
DC Taussig et al.
BLOOD (2005)
Over-expression of tumor necrosis factor-alpha in bone marrow biopsies from patients with myelodysplastic syndromes: relationship to anemia and prognosis
G Stifter et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2005)
Cognitive impairment, fatigue, and cytokine levels in patients with acute myelogenous leukemia or myelodysplastic syndrome
CA Meyers et al.
CANCER (2005)
FCGR3A and FCGR2A polymorphisms may not correlate with response to alemtuzumab in chronic lymphocytic leukemia
TS Lin et al.
BLOOD (2005)
Importance of cellular microenvironment and circulatory dynamics in B cell immunotherapy
Q Gong et al.
JOURNAL OF IMMUNOLOGY (2005)
Gemtuzumab ozogamicin: A review of its use in acute myeloid leukaemia
C Fenton et al.
DRUGS (2005)
Constitutive repressor activity of CD33 on human monocytes requires sialic acid recognition and phosphoinositide 3-kinase-mediated intracellular signaling
F Lajaunias et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2005)
Phase I studies of interleukin (IL)-2 and rituximab in B-cell non-Hodgkin's lymphoma: IL-2 mediated natural killer cell expansion correlations with clinical response
WL Gluck et al.
CLINICAL CANCER RESEARCH (2004)
The innate mononuclear phagocyte network depletes B lymphocytes through Fc receptor-dependent mechanisms during anti-CD20 antibody immunotherapy
JJ Uchida et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2004)
Obstacles to cancer immunotherapy: expression of membrane complement regulatory proteins (mCRPs) in tumors
Z Fishelson et al.
MOLECULAR IMMUNOLOGY (2003)
CD33/Siglec-3 binding specificity, expression pattern, and consequences of gene deletion in mice
ECM Brinkman-Vand der Linden et al.
MOLECULAR AND CELLULAR BIOLOGY (2003)
The inhibitory effect of anti-CD33 monoclonal antibodies on AML cell growth correlates with Syk and/or ZAP-70 expression
L Balaian et al.
EXPERIMENTAL HEMATOLOGY (2003)
Treatment of relapsed or refractory acute myeloid leukemia with humanized anti-D33 monoclonal antibody HuM195
E Feldman et al.
LEUKEMIA (2003)
Inflammatory cells, cytokines and chemokines in breast cancer progression: reciprocal tumor-microenvironment interactions
A Ben-Baruch
BREAST CANCER RESEARCH (2003)
Differences in CD33 intensity between various myeloid neoplasms
I Jilani et al.
AMERICAN JOURNAL OF CLINICAL PATHOLOGY (2002)
Reduced effect of gemtuzumab ozogamicin (CMA-676) on P-glycoprotein and/or CD34-positive leukemia cells and its restoration by multidrug resistance modifiers
H Matsui et al.
LEUKEMIA (2002)
Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcγRIIIa gene
G Cartron et al.
BLOOD (2002)
Gemtuzumab ozogamicin, a potent and selective anti-CD33 antibody-calicheamicin conjugate for treatment of acute myeloid leukemia
PR Hamann et al.
BIOCONJUGATE CHEMISTRY (2002)
Circulating levels of thrombopoietic and inflammatory cytokines in patients with acute myeloblastic leukemia and myelodysplastic syndrome
HC Hsu et al.
ONCOLOGY (2002)
Monocyte-chemoattractant-protein-1-mediated migration of human monocytes towards blasts from patients with acute myeloid leukemia
MCJC Legdeur et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2001)
Calicheamicin-conjugated humanized anti-CD33 monoclonal antibody (gemtuzumab zogamicin, CMA-676) shows cytocidal effect on CD33-positive leukemia cell lines, but is inactive on P-glycoprotein-expressing sublines
K Naito et al.
LEUKEMIA (2000)
Expression of complement regulatory proteins CR1, DAF, MCP and CD59 in haematological malignancies
D Guc et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2000)
分享论文
